MARKET

SAVA

SAVA

Cassava Sciences
NASDAQ
2.040
-0.050
-2.39%
Opening 12:33 12/30 EST
OPEN
2.090
PREV CLOSE
2.090
HIGH
2.090
LOW
2.010
VOLUME
584.74K
TURNOVER
--
52 WEEK HIGH
4.980
52 WEEK LOW
1.150
MARKET CAP
98.55M
P/E (TTM)
-0.9282
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SAVA last week (1222-1226)?
Weekly Report · 1d ago
Cassava Closes Chapter On Investor Lawsuit With Around $31 Million Deal
Benzinga · 12/23 14:20
Cassava Sciences Reaches Settlement in Securities Class Action
TipRanks · 12/23 14:16
Cassava Sciences to pay $31.25M to settle securities class action litigation
TipRanks · 12/23 13:16
Cassava Sciences Agrees To Resolve Consolidated Securities Class Action Litigation Pending In US District Court For Western District Of Texas Austin Division; Cassava To Pay $31.25M To Complete Settlement
Benzinga · 12/23 13:02
CASSAVA SCIENCES INC: WILL PAY $31.25 MLN FOR COMPLETE SETTLEMENT AND RELEASE OF ALL CLAIMS
Reuters · 12/23 13:00
CASSAVA ANNOUNCES AGREEMENT TO SETTLE SECURITIES CLASS ACTION LITIGATION
Reuters · 12/23 13:00
CASSAVA SCIENCES: TO RESOLVE LITIGATION FILED IN US DISTRICT COURT IN TEXAS
Reuters · 12/23 13:00
More
About SAVA
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Webull offers Cassava Sciences Inc stock information, including NASDAQ: SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.